| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8234909 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 8 Pages |
Abstract
Bevacizumab with HFSRT is safe and well tolerated. Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Philip H. M.D., Fabio M. M.D., Kathryn M.D., Nimish A. M.D., Sasan M.D., Bob L. Ph.D., Stella M.D., Yoshiya M.D., FRCPC., Jenghwa Ph.D., Lauren E. M.D.,